sterna biologicals announces data with gata-3 specific dnazyme SB012 to be presented at Digestive Disease Week®

Marburg, Germany, May 29, 2018

  • Further insights and data from Phase 2a trial in ulcerative colitis

Sterna biologicals GmbH & Co. KG (sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced today that further insights and data from a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with its DNAzyme candidate SB012 will be presented at Digestive Disease Week® (DDW) in Washington, DC, June 2-5, 2018.

sterna biologicals announces phase IIa data with SB010 published in Respiratory Research

Marburg, Germany, April 19, 2018

  • Investigator initiated study sponsored and funded by DZL (German Center for Lung Research) in patients with moderate to severe eCOPD
  • Primary endpoint and key secondary endpoints met

Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced that data from a randomized, double-blind, placebo-controlled, multicenter phase IIa trial with SB010 in chronic obstructive pulmonary disease (COPD) patients with eosinophilic airway inflammation have been published in the peer-reviewed medical journal, Respiratory Research[i].

sterna biologicals reports phase 2a study data demonstrating efficacy of its gata 3 specific dnazyme formulation sb012 in patients with ulcerative colitis

Marburg, Germany, February 19, 2018

  • Data presented at the 13th Congress of ECCO (European Crohn's and Colitis Organisation).
  • SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active ulcerative colitis. This represents a further validation of GATA-3-antagonism for the treatment of a variety of chronic inflammatory diseases.

sterna biologicals GmbH & Co. KG ("sterna"), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced that positive data from the SECURE study (NCT 02129439), a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with its GATA-3 specific DNAzyme formulation SB012, were presented at the 13th Congress of ECCO (European Crohn's and Colitis Organisation).

sterna biologicals to participate in upcoming international conferences in H1 2018

Marburg, Germany, 01 February 2018
sterna biologicals GmbH & Co. KG (sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announces its participation in the following key scientific and partnering conferences in the first half of 2018:

13th Congress of ECCO - European Crohn's and Colitis Organisation
Date: February 14-17, 2018 in Vienna, Austria

Christian Pangratz appointed Chief Executive Officer of sterna biologicals

Marburg, Germany, 8 January 2018

sterna biologicals GmbH & Co. KG (Sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced today that the Company has appointed Christian M. Pangratz as Chief Executive Officer. He brings over 25 years of life sciences experience, notably in the areas of strategic planning, corporate and business development, alliance and project management, new product planning, marketing and sales.